Australia markets closed

Qualigen Therapeutics Inc (7R9.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.2620-0.0040 (-1.50%)
At close: 05:47PM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
Total revenue
0
0
0
5,654
Cost of revenue
-
-
4,303
4,332
Gross profit
-
-
680.801
1,321
Operating expenses
Research development
5,209
5,209
4,486
11,717
Selling general and administrative
6,096
6,096
10,275
12,268
Total operating expenses
11,305
11,305
14,761
23,984
Operating income or loss
-11,305
-11,305
-14,761
-22,663
Interest expense
1,525
1,525
34.397
-
Total other income/expenses net
349.776
349.776
907.203
4,729
Income before tax
-12,480
-12,480
-13,888
-17,892
Income tax expense
-4.793
-4.793
6.548
5.427
Income from continuing operations
-12,475
-12,475
-13,894
-17,897
Net income
-13,417
-13,417
-18,641
-17,897
Net income available to common shareholders
-13,417
-13,417
-18,641
-17,897
Basic EPS
-3.73
-2.65
-4.86
-6.10
Diluted EPS
-3.73
-2.65
-4.86
-6.10
Basic average shares
4,820
5,073
3,840
2,933
Diluted average shares
4,820
5,073
3,840
2,933